3351

524715

SUNPHARMA

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

SUN PHARMACEUTICAL IND L Share Price Today

SUN PHARMACEUTICAL IND L is currently trading at ₹1804, down by ₹3.69 from the previous close. The stock touched an intraday high of ₹1818.00 and a low of ₹1797.80 during the latest trading session. Over the past one year, SUN PHARMACEUTICAL IND L has delivered a return of 7.12%, while the stock has declined 2.05% in the last one month.

SUN PHARMACEUTICAL IND L performance

Today’s low Today’s high
₹ 1797.80 ₹ 1818.00
₹ 1807.70
52 week low 52 week high
₹ 1548.00 ₹ 1916.60
₹ 1807.70
Open Price ₹ 1818.00
Prev. Close ₹ 1807.70
Volume (Shares) 1243362.00
Total traded value ₹ 22476.25
Upper Circuit ₹ 1988.40
Lower Circuit ₹ 1627.00
info

Investment Returns

Over 1 Month -2.05% Over 3 Months -0.96% Over 6 Months 0.79% Over 1 Year 7.12%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

SUN PHARMACEUTICAL IND L fundamentals


  • Market cap (Cr) 4,33,727.80
  • P/E Ratio (TTM) 165.35
  • Beta 0.54
  • Book Value / share 93.23
  • Return on equity 17.83%
  • EPS (TTM) 12.51
  • Dividend yield 0.89%
  • Net profit/quarter (Cr) 608.70
info icon alternate text
  • Market cap (Cr) 4,33,619.80
  • P/E Ratio (TTM) 165.35
  • Beta 0.50
  • Book Value / share 93.23
  • Return on equity 17.83%
  • EPS (TTM) 12.51
  • Dividend yield 0.89%
  • Net profit/quarter (Cr) 608.70
info icon alternate text

SUN PHARMACEUTICAL IND L Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 4887.27
Operating Expense 4137.80
Net Profit 608.70
Net Profit Margin (%) 12.45
Earnings Per Share (EPS) 2.50
EBITDA 1391.90
Effective Tax Rate (%) 28.30
Particulars DEC 2025 (Values in Cr)
Revenue 5651.21
Operating Expense 4511.87
Net Profit 705.44
Net Profit Margin (%) 12.48
Earnings Per Share (EPS) 2.90
EBITDA 1679.80
Effective Tax Rate (%) 35.69
Particulars SEP 2025 (Values in Cr)
Revenue 4511.27
Operating Expense 3949.15
Net Profit 564.22
Net Profit Margin (%) 12.50
Earnings Per Share (EPS) 2.40
EBITDA 1256.38
Effective Tax Rate (%) 16.00
Particulars JUN 2025 (Values in Cr)
Revenue 5559.27
Operating Expense 4234.69
Net Profit 745.06
Net Profit Margin (%) 13.40
Earnings Per Share (EPS) 3.10
EBITDA 1725.60
Effective Tax Rate (%) 36.65
Particulars MAR 2025 (Values in Cr)
Revenue 7100.65
Operating Expense 4657.82
Net Profit 2041.97
Net Profit Margin (%) 28.75
Earnings Per Share (EPS) 8.30
EBITDA 3191.58
Effective Tax Rate (%) 23.05
Particulars MAR 2026 (Values in Cr)
Revenue 20609.02
Operating Expense 16833.51
Net Profit 2623.42
Net Profit Margin (%) 12.72
Earnings Per Share (EPS) 10.90
EBITDA 6053.68
Effective Tax Rate (%) 30.85
Particulars MAR 2025 (Values in Cr)
Revenue 22598.40
Operating Expense 18380.32
Net Profit 4228.08
Net Profit Margin (%) 18.70
Earnings Per Share (EPS) 17.60
EBITDA 7216.84
Effective Tax Rate (%) 15.03
Particulars MAR 2024 (Values in Cr)
Revenue 19843.53
Operating Expense 17072.26
Net Profit 2858.18
Net Profit Margin (%) 14.40
Earnings Per Share (EPS) 11.90
EBITDA 5834.35
Effective Tax Rate (%) 17.14
Particulars MAR 2023 (Values in Cr)
Revenue 20394.63
Operating Expense 16412.32
Net Profit 1690.72
Net Profit Margin (%) 8.29
Earnings Per Share (EPS) 7.00
EBITDA 3814.10
Effective Tax Rate (%) 2.89
Particulars MAR 2022 (Values in Cr)
Revenue 15518.50
Operating Expense 14416.51
Net Profit -99.99
Net Profit Margin (%) -0.64
Earnings Per Share (EPS) -0.40
EBITDA 2044.91
Effective Tax Rate (%) 132.58
Particulars MAR 2025 (Values in Cr)
Book Value / Share 301.00
ROE % 16.16
ROCE % 19.52
Total Debt to Total Equity 0.04
EBITDA Margin 31.49
Particulars MAR 2024 (Values in Cr)
Book Value / Share 265.36
ROE % 16.13
ROCE % 17.20
Total Debt to Total Equity 0.08
EBITDA Margin 28.63
Particulars MAR 2023 (Values in Cr)
Book Value / Share 233.38
ROE % 16.46
ROCE % 16.79
Total Debt to Total Equity 0.08
EBITDA Margin 27.59
Particulars MAR 2022 (Values in Cr)
Book Value / Share 200.11
ROE % 14.50
ROCE % 17.97
Total Debt to Total Equity 0.05
EBITDA Margin 29.19
Particulars MAR 2021 (Values in Cr)
Book Value / Share 193.65
ROE % 11.14
ROCE % 13.60
Total Debt to Total Equity 0.13
EBITDA Margin 27.80
Particulars MAR 2025 (Values in Cr)
Book Value / Share 101.45
ROE % 17.83
ROCE % 16.29
Total Debt to Total Equity 0.47
EBITDA Margin 31.13
Particulars MAR 2024 (Values in Cr)
Book Value / Share 98.76
ROE % 12.05
ROCE % 12.22
Total Debt to Total Equity 0.40
EBITDA Margin 28.78
Particulars MAR 2023 (Values in Cr)
Book Value / Share 98.98
ROE % 13.89
ROCE % 16.26
Total Debt to Total Equity 0.27
EBITDA Margin 32.43
Particulars MAR 2022 (Values in Cr)
Book Value / Share 102.48
ROE % -5.19
ROCE % 7.47
Total Debt to Total Equity 0.24
EBITDA Margin 24.56
Particulars MAR 2021 (Values in Cr)
Book Value / Share 112.28
ROE % 3.53
ROCE % 3.57
Total Debt to Total Equity 0.27
EBITDA Margin 17.35
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 11331.62
Total Assets 92100.58
Total Liabilities 92100.58
Total Equity 72485.95
Share Outstanding 239
Price to Book Ratio 17.11
Return on Assets (%) 11.86
Return on Capital (%) 14.7
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 10520.68
Total Assets 85499.65
Total Liabilities 85499.65
Total Equity 67125.94
Share Outstanding 239
Price to Book Ratio 16.41
Return on Assets (%) 11.20
Return on Capital (%) 13.69
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 5770.29
Total Assets 80743.59
Total Liabilities 80743.59
Total Equity 59315.47
Share Outstanding 239
Price to Book Ratio 9.93
Return on Assets (%) 10.49
Return on Capital (%) 12.93
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 5033.35
Total Assets 69807.77
Total Liabilities 69807.77
Total Equity 51066.11
Share Outstanding 239
Price to Book Ratio 8.93
Return on Assets (%) 4.68
Return on Capital (%) 6.29
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 6445.51
Total Assets 67666.73
Total Liabilities 67666.73
Total Equity 49479.83
Share Outstanding 239
Price to Book Ratio 5.32
Return on Assets (%) 4.29
Return on Capital (%) 5.48
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 910.50
Total Assets 43273.45
Total Liabilities 43273.45
Total Equity 24339.85
Share Outstanding 239
Price to Book Ratio 17.11
Return on Assets (%) 9.89
Return on Capital (%) 12.13
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 338.39
Total Assets 41064.79
Total Liabilities 41064.79
Total Equity 23694.40
Share Outstanding 239
Price to Book Ratio 16.41
Return on Assets (%) 6.96
Return on Capital (%) 8.23
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 421.28
Total Assets 40987.49
Total Liabilities 40987.49
Total Equity 23748.36
Share Outstanding 239
Price to Book Ratio 9.93
Return on Assets (%) 4.12
Return on Capital (%) 5.39
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 534.96
Total Assets 40765.48
Total Liabilities 40765.48
Total Equity 24587.95
Share Outstanding 239
Price to Book Ratio 8.93
Return on Assets (%) -0.24
Return on Capital (%) -0.34
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 360.98
Total Assets 43734.79
Total Liabilities 43734.79
Total Equity 26938.47
Share Outstanding 239
Price to Book Ratio 5.32
Return on Assets (%) 1.92
Return on Capital (%) 2.47
Particulars MAR 2025 (Values in Cr)
Net Income 13752.13
Cash from Operations 14548.93
Cash from Investing -5306.16
Cash from Financing -7905.82
Net change in Cash 860.11
Free Cash Flow 16677.51
Particulars MAR 2024 (Values in Cr)
Net Income 11087.89
Cash from Operations 13704.42
Cash from Investing -690.20
Cash from Financing -6710.16
Net change in Cash 4734.62
Free Cash Flow 15906.23
Particulars MAR 2023 (Values in Cr)
Net Income 9408.43
Cash from Operations 6469.17
Cash from Investing -7943.68
Cash from Financing 2376.07
Net change in Cash -608.28
Free Cash Flow 8554.75
Particulars MAR 2022 (Values in Cr)
Net Income 4481.32
Cash from Operations 8015.32
Cash from Investing -5724.74
Cash from Financing -5193.46
Net change in Cash -1933.66
Free Cash Flow 9510.36
Particulars MAR 2021 (Values in Cr)
Net Income 2799.37
Cash from Operations 7173.31
Cash from Investing 536.22
Cash from Financing -5980.48
Net change in Cash 726.11
Free Cash Flow 8343.44
Particulars MAR 2025 (Values in Cr)
Net Income 5030.57
Cash from Operations 4334.08
Cash from Investing -209.56
Cash from Financing -3831.18
Net change in Cash 158.03
Free Cash Flow 5044.59
Particulars MAR 2024 (Values in Cr)
Net Income 3449.65
Cash from Operations 49.45
Cash from Investing -262.91
Cash from Financing 473.95
Net change in Cash -81.38
Free Cash Flow 798.69
Particulars MAR 2023 (Values in Cr)
Net Income 1741.05
Cash from Operations 939.07
Cash from Investing -705.17
Cash from Financing 169.31
Net change in Cash -28.78
Free Cash Flow 1901.50
Particulars MAR 2022 (Values in Cr)
Net Income 306.86
Cash from Operations 5476.82
Cash from Investing -2702.10
Cash from Financing -4870.85
Net change in Cash 63.41
Free Cash Flow 6326.71
Particulars MAR 2021 (Values in Cr)
Net Income 855.57
Cash from Operations -178.84
Cash from Investing 1463.81
Cash from Financing -999.73
Net change in Cash 47.57
Free Cash Flow 629.23
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 32.40 13.39 1.56 248.29 23.12 38.85
BLISS GVS PHARMA LTD. 438.10 35.56 3.89 4646.32 118.35 462.70
CIPLA LTD. 1388.80 29.47 3.25 112193.56 1165.55 1672.20
FERMENTA BIOTECH LTD. 338.80 14.94 2.45 997.12 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 32.40 22.66 4.17 248.29 23.12 38.85
AMRUTAJAN HEALTH LTD 557.75 25.00 4.35 1612.49 490.00 789.95
ASTRAZENECA PHARMA IND LT 8243.90 107.66 23.61 20609.75 7630.00 10653.05
BLISS GVS PHARMA LTD. 438.10 47.26 4.02 4646.32 118.35 462.70

SUN PHARMACEUTICAL IND L shareholding pattern

Holding
8.48%
54.47%
15.93%
21.1%
1.42%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

SUN PHARMACEUTICAL IND L Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1807.70 0.75 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 1795.20
  • 26 Days 1804.40
  • 10 Days 1798.40
  • 50 Days 1791.40
  • 12 Days 1800.70
  • 100 Days 1768.10
  • 20 Days 1805.30
  • 200 Days 1744.30
1792.63 PIVOT
First Support 1780.27 First Resistance 1806.57 Second Support 1766.33 Second Resistance 1818.93 Third Support 1753.97 Third Resistance 1832.87
RSI 51.01 ADX 8.42 MACD -3.67 Williams % R -59.35 Commodity Channel Index (CCI) -35.54
Date 2026-06-12 Week 1560737.00 Same Day 641851.00 Month 1795073.00
1 Year 0.54 3 Year 0.53
Over 1 Month
-2.05% down
Over 1 Year
7.12% down
Over 3 Months
-0.96% down
Over 3 Years
22.41% down
Over 6 Months
0.79% down
Over 5 Years
21.70% down

SUN PHARMACEUTICAL IND L Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
07 Jul 2026 5.0 Final 07 Jul 2026 Equity shares
05 Feb 2026 11.0 Interim 05 Feb 2026 Equity shares
07 Jul 2025 5.5 Final 07 Jul 2025 Equity shares
06 Feb 2025 10.5 Interim 06 Feb 2025 Equity shares
12 Jul 2024 5.0 Final 12 Jul 2024 Equity shares
09 Feb 2024 8.5 Interim 09 Feb 2024 Equity shares
28 Jul 2023 4.0 Final 28 Jul 2023 Equity shares
08 Feb 2023 7.5 Interim 08 Feb 2023 Equity shares
19 Aug 2022 3.0 Final 22 Aug 2022 Equity shares
09 Feb 2022 7.0 Interim 10 Feb 2022 Equity shares
23 Aug 2021 2.0 Final 25 Aug 2021 Equity shares
09 Feb 2021 5.5 Interim 10 Feb 2021 Equity shares
19 Aug 2020 1.0 Final 21 Aug 2020 Equity shares
17 Feb 2020 3.0 Interim 18 Feb 2020 Equity shares
20 Aug 2019 2.75 Final 22 Aug 2019 Equity shares
17 Sep 2018 2.0 Final 19 Sep 2018 Equity shares
18 Sep 2017 3.5 Final 20 Sep 2017 Equity shares
08 Sep 2016 1.0 Final 10 Sep 2016 Equity shares
21 Oct 2015 3.0 Final 24 Oct 2015 Equity shares
11 Sep 2014 1.5 Final 13 Sep 2014 Equity shares
19 Sep 2013 2.5 Final 23 Sep 2013 Equity shares
14 Aug 2012 4.25 Interim 16 Aug 2012 Equity shares
02 Sep 2011 3.5 Final 06 Sep 2011 Equity shares
09 Sep 2010 13.75 Final 14 Sep 2010 Equity shares
21 Aug 2009 13.75 Final 25 Aug 2009 Equity shares
25 Aug 2008 10.5 Final 27 Aug 2008 Equity shares
15 Mar 2007 6.75 Final 16 Mar 2007 Equity shares
19 Sep 2005 0.0 Final 21 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
30 Jul 2013 29 Jul 2013 1:1
29 May 2004 27 May 2004 1:1
23 Mar 2000 06 Mar 2000 2:1
Ex-Date Old FV NEW FV Record Date
25 Nov 2010 5.0 1.0 26 Nov 2010
13 Jan 2003 10.0 5.0 21 Jan 2003
Dividend date Dividend amount Dividend type Record date Instrument type
07 Jul 2026 5.0 Final 07 Jul 2026 Equity shares
05 Feb 2026 11.0 Interim 05 Feb 2026 Equity shares
07 Jul 2025 5.5 Final 07 Jul 2025 Equity shares
06 Feb 2025 10.5 Interim 06 Feb 2025 Equity shares
12 Jul 2024 5.0 Final 12 Jul 2024 Equity shares
09 Feb 2024 8.5 Interim 09 Feb 2024 Equity shares
28 Jul 2023 4.0 Final 28 Jul 2023 Equity shares
08 Feb 2023 7.5 Interim 08 Feb 2023 Equity shares
19 Aug 2022 3.0 Final 22 Aug 2022 Equity shares
09 Feb 2022 7.0 Interim 10 Feb 2022 Equity shares
23 Aug 2021 2.0 Final 25 Aug 2021 Equity shares
09 Feb 2021 5.5 Interim 10 Feb 2021 Equity shares
19 Aug 2020 1.0 Final 21 Aug 2020 Equity shares
17 Feb 2020 3.0 Interim 18 Feb 2020 Equity shares
20 Aug 2019 2.75 Final 22 Aug 2019 Equity shares
17 Sep 2018 2.0 Final 19 Sep 2018 Equity shares
18 Sep 2017 3.5 Final 20 Sep 2017 Equity shares
08 Sep 2016 1.0 Final 10 Sep 2016 Equity shares
21 Oct 2015 3.0 Final 24 Oct 2015 Equity shares
11 Sep 2014 1.5 Final 13 Sep 2014 Equity shares
19 Sep 2013 2.5 Final 23 Sep 2013 Equity shares
14 Aug 2012 4.25 Interim 16 Aug 2012 Equity shares
02 Sep 2011 3.5 Final 06 Sep 2011 Equity shares
09 Sep 2010 13.75 Final 14 Sep 2010 Equity shares
21 Aug 2009 13.75 Final 25 Aug 2009 Equity shares
25 Aug 2008 10.5 Final 27 Aug 2008 Equity shares
15 Mar 2007 6.75 Final 16 Mar 2007 Equity shares
19 Sep 2005 0.0 Final 21 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
30 Jul 2013 29 Jul 2013 1:1
29 May 2004 27 May 2004 1:1
23 Mar 2000 06 Mar 2000 2:1
Ex-Date Old FV NEW FV Record Date
25 Nov 2010 5.0 1.0 26 Nov 2010
13 Jan 2003 10.0 5.0 21 Jan 2003

Top Gainers

Top Losers

Sun Pharmaceutical Industries Ltd Overview

Sun Pharmaceutical Industries Ltd, headquartered in India, is a global frontrunner in the pharmaceutical sector, holding the title of the largest pharmaceutical company in India. Since its establishment in 1981, Sun Pharma has dedicated itself to manufacturing, developing, and marketing an extensive array of branded and generic formulations along with Active Pharmaceutical Ingredients (APIs). The company showcases a diverse product portfolio targeting various chronic and acute treatments, available in forms ranging from injectables to capsules. With significant achievements like being the 11th largest in the US generics market as of September 2023, and leading the Indian branded generics market, Sun Pharma continues to expand its global footprint across emerging and developed markets, including strategic acquisitions to enhance its market position. It operates around 43 manufacturing facilities worldwide and is distinguished for its comprehensive R&D capabilities, focusing on specialty/complex products development. The company's international presence is marked by a sales force of approximately 2,200 representatives, selling products in about 80 countries with a focus on areas like dermatology, ophthalmology, and onco-dermatology. Through strategic acquisitions and a focus on R&D, Sun Pharma has solidified its standing as a pivotal player in the global pharmaceutical industry, combining extensive manufacturing capabilities with a robust product portfolio to address diverse medical needs.

Sun Pharma share result highlights

In the second quarter of fiscal year 2024-25, Sun Pharmaceutical Industries Ltd. reported a consolidated net profit of ₹3,040 crore, marking a 28% increase from ₹2,375 crore in the same period the previous year. Revenue from operations rose by 9% year-on-year to ₹13,291 crore, surpassing market estimates. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) grew 24% year-on-year to ₹3,939 crore, with a margin of 29.6%. Formulation sales in India increased 11% year-on-year to ₹4,265 crore, representing 32% of total sales. These robust financial results have positively influenced the Sun Pharma share price, reflecting increased investor confidence.

Sun Pharma share annual reports

The 2023-24 annual report of Sun Pharmaceutical Industries Ltd. provides comprehensive insights into its financial performance and strategic initiatives. The company achieved a total income of ₹45,000 crore, registering a growth of 5% from the previous year. The report highlights Sun Pharma's focus on expanding its product portfolio, enhancing operational efficiency, and implementing cost optimisation measures. These efforts have contributed to a stable Sun Pharma share price by showcasing the company's commitment to growth and profitability.

Sun Pharma share dividend

For the fiscal year 2023-24, Sun Pharmaceutical Industries Ltd. declared a total dividend of ₹12 per share, reflecting its commitment to returning value to shareholders. This consistent dividend payout, supported by strong financial performance, has positively impacted the Sun Pharma share price by enhancing investor confidence.

Popular FAQs

1. Who is the CEO of Sun Pharma Ltd?

As of November 2024, the Managing Director of Sun Pharmaceutical Industries Ltd. is Mr. Dilip Shanghvi. He oversees the company's operations and strategic initiatives, influencing the Sun Pharma share price through effective leadership and business expansion.

 

2. When was Sun Pharma Ltd established?

Sun Pharmaceutical Industries Ltd. was established in 1983. Over the decades, it has grown into one of India's leading pharmaceutical companies, impacting the Sun Pharma share price through its extensive operations and market presence.

 

3. What factors influence Sun Pharma Ltd share price fluctuations?

The Sun Pharma share price is influenced by various factors, including the company's financial performance, expansion of product portfolios, regulatory developments, and broader economic conditions. Additionally, market demand for pharmaceutical products, competition, and research and development outcomes play significant roles in determining share price movements.

 

4. Is Sun Pharma debt free?

No, Sun Pharmaceutical Industries Ltd. is not entirely debt-free. The company utilises debt financing to fund its capital-intensive projects and expansion plans. However, it maintains a balanced debt-to-equity ratio, ensuring financial stability and the ability to meet its obligations without adversely affecting the Sun Pharma share price.

 

5. What is the CAGR of Sun Pharma share?

Over the past five years, the Compound Annual Growth Rate (CAGR) of Sun Pharma shares has been approximately 10%. This indicates a steady growth in the Sun Pharma share price, reflecting the company's consistent financial performance and strategic initiatives.

 

6. How has the Sun Pharma share price performed over the past year?

Over the past year, the Sun Pharma share price has experienced fluctuations influenced by market conditions and company performance. As of November 2024, the share price has shown a modest increase compared to the same period last year, reflecting investor confidence in the company's strategic direction and financial health.

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Sun Pharmaceutical Industries Ltd?

Answer Field

Sun Pharmaceutical Industries Ltd share price is for NSE ₹ 1,804.00 & for BSE ₹ 1,804.45 as on Jun 15 2026 11:40 AM.

What is the Market Cap of Sun Pharmaceutical Industries Ltd Share?

Answer Field

The market cap of Sun Pharmaceutical Industries Ltd for NSE ₹ 0.04 & for BSE ₹ 0.04 as on Jun 15 2026 11:40 AM.

What is the 52 Week High and Low of Sun Pharmaceutical Industries Ltd?

Answer Field

The 52 Week High and Low of Sun Pharmaceutical Industries Ltd for NSE is ₹ 1,916.60 and ₹ 1,548.00 and for BSE is ₹ 1,917.15 and ₹ 1,547.25.

What is 1 year return for Sun Pharmaceutical Industries Ltd?

Answer Field

The 1 year returns on the stock has been 7.12%.

What is the P/E Ratio of Sun Pharmaceutical Industries Ltd Share?

Answer Field

As on Jun 15 2026 11:40 AM the price-to-earnings (PE) ratio for Sun Pharmaceutical Industries Ltd share is 165.35.

What is the PB ratio of Sun Pharmaceutical Industries Ltd Share?

Answer Field

As on Jun 15 2026 11:40 AM, the price-to-book (PB) ratio for Sun Pharmaceutical Industries Ltd share is 93.23.

How to Buy Sun Pharmaceutical Industries Ltd Share?

Answer Field

You can trade in Sun Pharmaceutical Industries Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Sun Pharmaceutical Industries Ltd Share on Bajaj Broking App?

Answer Field

To buy Sun Pharmaceutical Industries Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Sun Pharmaceutical Industries Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

Who is the CEO of Sun Pharma Ltd?

Answer Field

As of November 2024, the Managing Director of Sun Pharmaceutical Industries Ltd. is Mr. Dilip Shanghvi. He oversees the company's operations and strategic initiatives, influencing the Sun Pharma share price through effective leadership and business expansion.

When was Sun Pharma Ltd established?

Answer Field

Sun Pharmaceutical Industries Ltd. was established in 1983. Over the decades, it has grown into one of India's leading pharmaceutical companies, impacting the Sun Pharma share price through its extensive operations and market presence.

What factors influence Sun Pharma Ltd share price fluctuations?

Answer Field

The Sun Pharma share price is influenced by various factors, including the company's financial performance, expansion of product portfolios, regulatory developments, and broader economic conditions. Additionally, market demand for pharmaceutical products, competition, and research and development outcomes play significant roles in determining share price movements.

Is Sun Pharma debt free?

Answer Field

No, Sun Pharmaceutical Industries Ltd. is not entirely debt-free. The company utilises debt financing to fund its capital-intensive projects and expansion plans. However, it maintains a balanced debt-to-equity ratio, ensuring financial stability and the ability to meet its obligations without adversely affecting the Sun Pharma share price.

What is the CAGR of Sun Pharma share?

Answer Field

Over the past five years, the Compound Annual Growth Rate (CAGR) of Sun Pharma shares has been approximately 10%. This indicates a steady growth in the Sun Pharma share price, reflecting the company's consistent financial performance and strategic initiatives.

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|